Basilea Pharmaceutica is a Switzerland‐based biopharmaceutical company headquartered in Basel, focused on the development and commercialization of innovative therapies in anti‐infectives and oncology. Since its founding in 2000, the company has concentrated on addressing significant unmet medical needs, particularly in the treatment of invasive fungal infections, resistant bacterial infections and selected cancer indications. Basilea’s research and development efforts combine small‐molecule expertise with targeted licensing collaborations to advance its product pipeline.
In the anti‐infectives space, Basilea’s flagship product is isavuconazole (marketed as Cresemba), an antifungal agent approved for the treatment of invasive aspergillosis and mucormycosis. Cresemba has been licensed to Astellas Pharma for commercialization in North America, Europe and Asia, providing broad geographic reach through an established global partner. The company also developed ceftobiprole (marketed as Zevtera or Mabelio), a next‐generation cephalosporin antibiotic active against methicillin‐resistant Staphylococcus aureus (MRSA) and other resistant pathogens. Basilea has granted Johnson & Johnson commercialization rights for ceftobiprole in select markets.
Oncology represents the second pillar of Basilea’s portfolio, with derazantinib (an FGFR inhibitor) in clinical development for patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 gene fusions. The company is exploring potential expansion of derazantinib into additional solid tumor types and combining it with other targeted agents. Basilea’s R&D organization operates out of Basel, Switzerland, and leverages external collaborations to accelerate clinical programs while maintaining a lean internal structure.
Through partnerships with global pharmaceutical companies and a focus on specialty hospital markets, Basilea Pharmaceutica serves patients across Europe, North America and Asia. The company’s business model emphasizes licensing and co‐development agreements to maximize the commercial potential of its products. Basilea’s management team and scientific board bring decades of experience in drug development, regulatory affairs and global commercialization, guiding the company’s efforts to deliver new therapies for serious infections and cancer.
AI Generated. May Contain Errors.
Free BPMUF Stock Alerts